Title: Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization.
Journal: Journal of pharmaceutical and biomedical analysis 20120325
Title: Delayed elimination of SN-38 in cancer patients with severe renal failure.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20110201
Title: Fast liquid chromatography-tandem mass spectrometry method for routine assessment of irinotecan metabolic phenotype.
Journal: Therapeutic drug monitoring 20101001
Title: The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
Journal: European journal of cancer (Oxford, England : 1990) 20100701
Title: Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats.
Journal: Cancer chemotherapy and pharmacology 20100401
Title: Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601
Title: Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.
Journal: Journal of neuro-oncology 20090401
Title: Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20090201
Title: Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
Journal: British journal of cancer 20081021
Title: Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.
Journal: Chemico-biological interactions 20080811
Title: Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients.
Journal: The pharmacogenomics journal 20080601
Title: A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort.
Journal: Current drug metabolism 20070201
Title: [Pharmacokinetic study of cancer chemotherapy].
Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20060901
Title: The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20060701
Title: In vivo disposition of irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody cetuximab.
Journal: Anticancer research 20060101
Title: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20050301
Title: Pharmacokinetics and metabolism of irinotecan combined with capecitabine in patients with advanced colorectal cancer.
Journal: Anticancer research 20050101
Title: New approaches to prevent intestinal toxicity of irinotecan-based regimens.
Journal: Cancer treatment reviews 20041001
Title: Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
Journal: The Journal of pharmacy and pharmacology 20040601
Title: A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20040301
Title: Biliary excretion of irinotecan and its metabolites.
Journal: Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20040123
Title: UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers.
Journal: Anticancer research 20040101
Title: Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.
Journal: Cancer research 20031201
Title: [Pharmacokinetic study of CPT-11, SN-38 and SN-38 glucuronide in the ascites, plasma and bile after intraperitoneal administration of CPT-11].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20021101
Title: Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.
Journal: Biochemical pharmacology 20020215
Title: Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
Journal: Cancer research 20020101
Title: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
Journal: The pharmacogenomics journal 20020101
Title: Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.
Journal: Biochemical and biophysical research communications 20011109
Title: Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma.
Journal: Anticancer research 20010101
